Published in Leukemia on January 17, 2008
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Proteasome inhibitors in the treatment of multiple myeloma. Leukemia (2009) 1.68
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Kidney disease and multiple myeloma. Clin J Am Soc Nephrol (2013) 1.26
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica (2013) 1.19
Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist (2010) 1.04
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica (2013) 1.03
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica (2011) 1.00
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol (2011) 0.96
Kidney disease associated with plasma cell dyscrasias. Blood (2010) 0.95
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia (2010) 0.94
Bortezomib in multiple myeloma: systematic review and clinical considerations. Curr Oncol (2014) 0.93
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol (2012) 0.90
Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case report. Ochsner J (2014) 0.87
Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics (2010) 0.84
Multiple myeloma in the very old: an IASIA conference report. J Natl Cancer Inst (2014) 0.83
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol (2012) 0.83
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica (2015) 0.83
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. J Cancer Res Clin Oncol (2013) 0.81
Novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol (2012) 0.80
Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Support Care Cancer (2015) 0.79
Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy. Blood Cancer J (2015) 0.78
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. Br J Haematol (2016) 0.78
Current Trends of Renal Impairment in Multiple Myeloma. Kidney Dis (Basel) (2016) 0.77
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. Haematologica (2014) 0.77
Caffeic Acid Phenylethyl Ester and MG-132 Have Apoptotic and Antiproliferative Effects on Leukemic Cells But Not on Normal Mononuclear Cells. Transl Oncol (2009) 0.76
Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment? Haematologica (2014) 0.75
Arsenic Trioxide Combined with VCMP or VAD Chemotherapy in Patients with Refractory or Relapsed Multiple Myeloma in a Single Institution of China. Indian J Hematol Blood Transfus (2014) 0.75
Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies. Medicine (Baltimore) (2016) 0.75
Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report. BMC Nephrol (2017) 0.75
Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone. Case Rep Nephrol (2014) 0.75
Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk (2015) 0.75
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response. Invest New Drugs (2010) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med (1996) 10.69
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med (1995) 9.72
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res (2001) 6.93
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med (1995) 6.52
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 4.76
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
Single neurons in prefrontal cortex encode abstract rules. Nature (2001) 4.05
Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA (1992) 3.86
bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA. Mol Cell Biol (1997) 3.62
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood (1999) 3.44
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Silicon and Dust Deposits in the Tissues of Persons Without Occupational Exposure to Siliceous Dusts. Can Med Assoc J (1936) 3.21
B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol (1983) 3.09
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol (2011) 3.07
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 2.98
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood (1984) 2.74
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Structure and mechanism of endo/exocellulase E4 from Thermomonospora fusca. Nat Struct Biol (1997) 2.49
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene (2001) 2.39
Hypotensive reactions: a previously uncharacterized complication of platelet transfusion? Transfusion (1996) 2.37
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 2.33
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia (2005) 2.30
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 2.30
Multiple myeloma: increasing evidence for a multistep transformation process. Blood (1998) 2.29
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia (2007) 2.28
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia (2009) 2.25
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol (2008) 2.23
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene (2001) 2.04
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood (1993) 2.02
[Catheter ablation of chronic atrial fibrillation using circumferential and complex linear lesions in the left atrium: modes of arrhythmia termination and long-term clinical outcome]. Vnitr Lek (2007) 2.02
Hepatitis B transmission from contaminated cryopreservation tank. Lancet (1995) 1.99
Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol (2001) 1.94
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet (1997) 1.94
[Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]. Ned Tijdschr Geneeskd (2002) 1.93
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol (2001) 1.89
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene (2006) 1.89
Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia (2009) 1.84
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia (2013) 1.84
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia (2006) 1.83
Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG) Ann Intern Med (1994) 1.81
The accuracy of self-reported disability days. Med Care (1994) 1.81
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia (2006) 1.79
Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol (1995) 1.77
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol (2003) 1.75
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol (1997) 1.75
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia (2004) 1.71
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
Vole Acid-Fast Bacillus Vaccination in Experimental Tuberculosis. Can Med Assoc J (1943) 1.69
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol (2001) 1.68
IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol (1997) 1.68
Preliminary clinical experience with a thermal balloon endometrial ablation method to treat menorrhagia. Obstet Gynecol (1994) 1.68
Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann Oncol (2002) 1.67
High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol (1998) 1.61
Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol (2002) 1.61